Boehringer Ingelheim reports survodutide meets cardiovascular safety endpoint
- The trial met its primary endpoint: 5P-MACE risk was not increased versus placebo (HR 0.89; 95% CI 0.67–1.18).
- At week 72, weight loss reached 13.7% and waist circumference fell by up to 11.96 cm, using the supplementary secondary estimand.
- Systolic blood pressure fell by up to 6.68 mmHg at week 72, compared with 1.76 mmHg with placebo.
- GI-related discontinuations occurred in 19.3% and 20.8% of participants on 3.6 mg and 6.0 mg doses, respectively, versus 1.9% on placebo.
Cardiovascular outcomes
Boehringer Ingelheim reported that the Phase III SYNCHRONIZE-CVOT trial met its primary endpoint. In adults with obesity or overweight and elevated cardiovascular risk, survodutide did not increase the risk of 5P-MACE versus placebo (HR 0.89; 95% CI 0.67–1.18), meeting the non-inferiority criterion. The trial also found no increased risk of 3P-MACE (HR 0.84; 95% CI 0.60–1.18).
Cardiometabolic measures and tolerability
At week 72, results using the supplementary secondary estimand showed weight loss of up to 13.7%, compared with 2.0% for placebo; waist circumference reduction of up to 11.96 cm, compared with 2.74 cm; and systolic blood pressure reduction of up to 6.68 mmHg, compared with 1.76 mmHg. The trial also reported reductions in hs-CRP and triglycerides.
The most commonly reported adverse events were gastrointestinal, including nausea, vomiting, diarrhea and constipation, mostly mild to moderate. Discontinuation due to GI events was 19.3% with 3.6 mg and 20.8% with 6.0 mg, versus 1.9% with placebo. Boehringer Ingelheim said the trial protocol allowed limited flexibility for managing adverse events during dose escalation.
Development plans
Survodutide is an investigational glucagon/GLP-1 dual receptor agonist and has not been approved; its efficacy and safety have not been established. The company said it is moving forward with global regulatory submissions in obesity. Further trials are investigating its use in obesity, type 2 diabetes and MASH.
Source: Boehringer Ingelheim